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ORIGINAL ARTICLE
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Substance Addiction Treatment with Buprenorphine/naloxone
Kenneth Blum a,b,c,d,e,f,g , David Hanh , Edward J. Modestino i , Scott Saundersb , A. Kennison Roy IIIj , W. Jacobsk ,
Darryl S. Inabal , David Baronc , Marlene Oscar-Bermann , Mary Hauserb , Rajendra D. Badgaiyanm , David E. Smithp ,
John Feminob , and Mark S. Goldo
a
Department of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, USA; b Division of Addiction
Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA; c Departments of Psychiatry & Behavioral Sciences, Keck School of
Medicine of USC, Los Angeles, California, USA; d Department of Psychology, Eötvös Loránd University, Institute of Psychology, Budapest,
Hungary; e Human Integrated Services Unit, University of Vermont Centre for Clinical & Translational Science, College of Medicine, Burlington,
Vermont, USA; f Division of Neuroscience Research & Addiction Therapy, Shores Treatment & Recovery Center, Port Saint Lucie, Florida, USA;
g
Geneus Health, San Antonio, Texas, USA; h Department of Management Science and Statistics, University of Texas at San Antonio, Texas, USA;
i
Department of Psychology, Curry College, Milton, Massachusetts, USA; j Behavioral Medical Corporation, Metairie, Louisiana, USA; k Division of
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Washington University School of Medicine, St. Louis, Missouri, USA; p Department of Pharmacology, University of San Francisco, San Francisco,
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ABSTRACT

Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and
low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked
at compliance and abstinence in one sample. Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern
USA in 2010 and 2011. Results: Part 1: Bup/nal was present in 93.4% of first (n = 1,282; p < .0001) and
92.4% of last (n = 1,268; p < .0001) urine samples. Concomitantly, unreported illicit drugs were present
in 47.7% (n = 655, p = .0261) of samples. Patients who were compliant to the bup/nal prescription were
more likely than noncompliant patients to be abstinent during treatment (p = .0012; odds ratio = 1.69
with 95% confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed
a significant improvement in both compliance (p < 2.2 × 10−16 ) and abstinence (p < 2.2 × 10−16 ) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with
bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted
therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical
datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration
in future investigations.

Introduction
Substance-seeking behaviors have negative and devastating consequences (Policy, 2004; Rehm et al., 2009).
Opioid-use disorder is associated with many adverse,
health and social consequences for society: infectious
disease transmission, elevated healthcare costs, public
disorder, crime and fatal overdose (Lynch et al., 2014).
A combination of buprenorphine a partial mu-receptor

KEYWORDS

Abstinence;
buprenorphine/naloxone;
compliance; opioid
maintenance therapy
programs; substance-use
disorder; urine drug screens

agonist that blocks kappa opioid-type receptors, and
naloxone a low-dose narcotic delta/mu-receptor antagonist, to prevent injection by inducing withdrawal (Chiang
& Hawks, 2003; Wesson & Smith, 2010) is being used for
opioid maintenance therapy programs. The Federal Drug
Addiction Treatment Act 2000 allows physicians who
meet certain qualifications to treat opioid-dependent
patients with buprenorphine and naloxone (bup/nal)
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combination. Many clinical studies have established
that bup/nal maintenance is as effective as methadone
maintenance, in reducing illicit opioid use and retaining
patients in medication-assisted treatment (MAT) programs (Jaffe & O’Keeffe, 2003; Volkow, Frieden, Hyde, &
Cha, 2014).
In 2014, Mattick et al. used Cochrane Collaboration
methodology to evaluate buprenorphine and methadone
maintenance compared to placebo in 31 trials that
included 5,430 participants. They found that when fixed
medium or high doses are used, buprenorphine and
methadone are equally effective for treatment retention
in and suppression of illicit opioid use. Specifically, they
found buprenorphine at dosages greater than 2 mg per
day maintains treatment retention better than placebo.
While at 16 mg or more per day, buprenorphine was found
to reduce illicit substance use compared with placebo as
monitored by urinalysis. However, buprenorphine retains
fewer people compared to methadone, when doses are low
and fixed or flexibly delivered (Mattick, Breen, Kimber, &
Davoli, 2014).
Two hypotheses formed the basis of this retrospective
post hoc study. They were that patients in programs being
treated with bup/nal: (1) adhere to prescribed bup/nal
treatment medications and (2) abstain from illicit drug
use during treatment.
Previous studies have used biological markers to determine compliance to known dosages of treatment medications or measure nonabstinence during treatment (Balhara & Jain, 2012; Baros, Latham, Moak, Voronin, &
Anton, 2007; Gerra, Fantoma, & Zaimovic, 2006; Kumari
et al., 2016; McDermott et al., 2015; Moore et al., 2016; Pal
Singh Balhara & Jain, 2012). Other studies have focused
on meaningful comparisons regarding treatment modalities, efficacy methadone vs. bup/nal, and determination
of risk factors for compliance and treatment success.
Many of these studies have used short follow-up periods, and researchers have focused largely on retention
rates, chart reviews, instances of buprenorphine administration, interviews, self-report of heroin use and criminal activity, and telephone or internet communication,
to measure adherence and abstinence (Fareed et al., 2014;
Maas, Barton, Maskrey, Pinto, & Holland, 2013; Mattick
et al., 2014; Moore et al., 2016; Parran et al., 2010; Tkacz,
Severt, Cacciola, & Ruetsch, 2012).
This study, however, presents a systematic analysis of
a large sample of data from patient urine drug screens
(UDS) from a variety of treatment programs in five states
over 2 years. Compliance with prescribed medication
and nonabstinence during bup/nal maintenance treatment were measured in a single sample of analytes (Blum
et al., 2011; Blum et al., 2014; Hill et al., 2013).
The statistical analysis has two parts. Part 1 examines
compliance and abstinence in first and last urine samples
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collected during treatment in 2010 and 2011 and explores
outcomes across states, treatment modality and as a
function of the level of care. Part 2 focuses on trends in
compliance and abstinence over time.
Comprehensive analysis of reported drugs
The “Comprehensive Analysis of Reported Drugs”
(CARDTM ) is a reporting system that uses laboratory
results from validated urine drug testing profiles of
prescription and illicit drugs.
The comprehensive drug-monitoring tools utilized
in CARDTM include 16 testing methodologies (standard enzyme immunoassay and liquid chromatographytandem mass spectrometry measured by quantitative
creatinine-adjusted immunoassay). These methods are
employed to identify substances or metabolites from 28
distinct drug categories. With this process, 125 distinct
drugs or metabolites can be determined. These methods have been developed to assist clinicians in managing
patients with precision at intake, during treatment, and
to determine individual and program outcomes (McCarberg, 2011). In summary, CARDTM compares the selfreport of illicit substance use and prescribed medication
use, to the objective detection of drugs and medications
measured by quantitative creatinine-adjusted immunoassay and molecular identification techniques.
The basis of the CARDTM methodology is that when
the test is ordered the drugs prescribed by the physician and the illicit drugs reported by the patient are
noted. Drugs present in the body have been scientifically proven to exhibit specific conditional results on drug
tests. The CARDTM correlation process determines specific conditional drug tests results, reports on whether
or not the drugs identified in the test are “expected” or
“not expected” and assigns a written comment. The results
are provided to the physician for each reported drugto-analyte pair depending on the conditions established
in the laboratory order; the self- and physician-reported
drugs are “expected.” Physicians are sent “alerts” regarding “not expected” test results in the report. Nearly 2,000
pharmacists’ notes and associated conditions have been
defined and can be analyzed automatically. All expected
Food and Drug Administration (FDA) approved drugs
for Substance Use Disorder (SUD) treatment and patientreported substances are included in each UDS. Due to
comorbidity, the following drug classes: anabolic steroids,
antidepressants, hallucinogens, inhalants, muscle relaxants, opioids, psychostimulants, psychotropic, sedatives,
hypnotics, and depressants are also included in the screen.
Expected or not expected results guide treatment
plans and measure outcomes. Because drugs are metabolized into other reportable substances, the possibility
exists that test results can be open to misinterpretation.
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Table . Sample distribution over treatment modality, level of care, and minimum days between the samples.
Modality
In-patient (IN)

n (%)

Level of care

n (%)

Minimum days between the samples

 (.)

In-patient (IP)
Residential facility (RES)
Intensive out-patient (IOP)
Out-patient (OP)
Opioid treatment program (OTP)

 (.)
 (.)
 (.)
 (.)
 (.)
, (.)







Out-patient (OUT)

, (.)

Total

, ()

Clinicians are given access to Pharm. D. consultants to
assist them in result interpretation. The information is
used in clinical interactions with the client.
This innovative monitoring tool can also aggregate
data from each client, within a clinical practice, to
establish the percentages of clients who are compliant
with medications-prescribed doses during treatment. The
analysis also detects unexpected illicit drug use (nonabstinence) in patients tested, relative to expected reported
drug use and aggregates that data.
A detailed explanation of CARDTM methodology can
be found in the “CARD Rule Sets” in Supporting information S1 in a previously published paper (Blum et al., 2014).
The FDA approved MAT; bup/nal is the focus of this data
analysis.

Method
This study reports the results of a statistical analysis
of unidentifiable data from CARDTM , privately held at
Dominion Diagnostics, LLC, North Kingston, RI. The
data were used to evaluate treatment adherence and nonabstinence in a large clinical cohort from some eastern
states in the United States. The Dominion pharmacy staff
did determine whether prescription medications present
in the results were licit or illicit. Before being accessed
for this statistical analysis as part of the CARD process,
each entry was tagged as being prescribed, or other, examples are, prescribed benzodiazepines, stimulant medications to treat Attention Deficit Hyperactivity Disorder
(ADHD) or other substances such as opioids prescribed
for an operative procedure or comorbid conditions. The
entire data set (raw data) was deidentified and then vetted independently by the statistician.
The ethics committee from Path Foundation NY
waived Institutional Review Board (IRB) approval and
the requirement of consent by individual patients for the
use of this database for this research analysis on November 29th, 2012. The nonpublic, anonymized data can be
provided to researchers with prior written approval by
Dominion Diagnostics, LLC.
Subject population
This present study is a statistical analysis of a subset of the data from a large cohort of 10,570 patients

(including nontreatment patients) collected from
addiction-treatment centers across six eastern states
in the United States from 2010 to 2011.
The subset used in this study is, of data from the initial
large cohort, restricted to those patients taking bup/nal
(n = 1,372) stratified by treatment modality and five different levels of care (Table 1) from five states (Table 2).
The first statistical analysis (Part 1) was of data from the
first and last urine specimens 2010 and 2011. Although
some patients yielded multiple urine samples, to ensure
the uniformity of the collection scheme, only the first
and last urine samples were considered. In Table 1, the
minimum number of calendar days between specimens
was taken into consideration, and some patients who had
changed the level of care were excluded.
The second statistical analysis (Part 2) was to determine
trends in compliance and abstinence rates over time. The
focus was to analyze data from all urine samples collected
during the year 2011 from each patient prescribed the
bup/nal combination.
Summary of demographic statistics
Part 
The distribution of patients across two modalities and five
levels of care are presented in Table 1. Most of the sample (97.4%) consisted of the out-patients of which 13.6%
were in opioid treatment programs. It was found that
11.1% of the patients (n = 152) had both the first and last
urine specimens collected in 2010, while 46.7% (n = 641)
had both specimens collected in 2011. The rest of 42.2%
(n = 579) had the first urine specimen collected in 2010
and the last specimen collected in 2011. That resulted in
a total of 1,372 patients with first and last urine samples,
who were on at least one prescription medication including bup/nal (n = 1,372; total 2,744 specimens). Indeed
Table . Sample distribution over states.
State
Maryland (MD)
Maine (ME)
North Carolina (NC)
Rhode Island (RI)
Vermont (VT)
Total

Sample size

Percentage






,

.%
.%
.%
.%
.%
.%
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82.3% of the patients (n = 1,129) were prescribed bup/nal
alone. The distribution of the number of days between the
first and last urine samples is heavily right-skewed with
ranges from 15 to 717 days. The median is 189 days with
the interquartile range of 252 days. The mean and standard deviation of the sample are 224.6 and 165.2 days,
respectively.
Patient distribution across five eastern states in the
United States is presented in Table 2. South Carolina
had only one bup/nal patient observation and hence was
excluded from the analysis. The sample size is mostly
skewed toward Maine and Vermont (VT).
Part 
Trends in compliance and abstinence rates in UDS
obtained from individuals, up to the extreme of 94 times,
were examined. The initial subset (n = 1,379) included a
few patients excluded from the first analysis because they
had changed their level of care during 2011. The final subset was (n = 1,299) after 80 patients who had only one
urine specimen in 2011 were excluded. It is noteworthy
that Dominion Diganostics, LLc does not endorse such a
high rate of UDS.
Statistical analysis
Statistical analysis was conducted using the discrete contingency analyses, the two-level binomial logistic regression model, and the generalized linear mixed model
(GLMM) in the R package version 2.15.0.
The definitions of the terms used in this analysis are as
follows:
Compliance: patient compliance to prescribed treatment medications during in-patient or out-patient recovery program.
r Compliance both: bup/nal detected in both in the
first and last urine samples tested.
r Compliance first: bup/nal detected in the first urine
sample.
r Compliance last: bup/nal detected in the last urine
sample.
Abstinence: patient abstinence from all nonprescribed
licit or illicit psychoactive substances during treatment.
r Abstinence both: CARDTM did not detect any analyte that was not attributed to a reported prescription
in the first and last urine samples tested.
r Abstinence first: CARDTM did not detect any analyte
that was not attributed to a reported prescription in
the first urine sample.
r Abstinence last: CARDTM did not detect any analyte
that was not attributed to a reported prescription in
the last urine sample.
Note that “compliance both” implies that “compliance
first” as well as “compliance last” were present in both tests
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from the same individual. The same logic applies to “abstinence both.”
The Fisher’s exact test was used to evaluate differences
in adherence to treatment medications and abstinence
rates according to the type of treatment (in-patient vs.
out-patient) and level of care. Also, every statistical analysis herein comes with a controlled Type-I error rate.

Results
Part 1. Statistical analysis of first and last urine
samples 2010–2011 (n = 1,372)
There is significant (Table 7) statistical evidence that
compliant patients are more likely to be abstinent during treatment compared to noncompliant patients. Prescribed bup/nal was present in both the first and last urine
samples in 87.7% of the subjects (n = 1,203), demonstrating strong compliance to the prescribed drug (p <
.0001). Concomitantly in the same sample, we found that
47.7% (n = 655) were still misusing some psychoactive
substances during treatment (p = .0261). The association
between noncompliance to the medication and continued
substance misuse during treatment was found to be statistically significant (p = .0019).
Subjects who were compliant to the bup/nal prescription were more likely to be abstinent during treatment than the noncompliant subjects (p = .0012; odds
ratio = 1.69 with 95% confidence interval [1.210, 2.354]).
Compliance with taking bup/nal was found in both
the first and last urine specimens of 87.7% of patients
(n = 1,203; p < .0001). In the first urine sample, 93.4%
of patients (n = 1,282; p < .0001) were compliant and
in the last urine sample of 92.4% of patients (n = 1,268;
p < .0001). Over the course of two urine specimen collections, it was found that only 1.8% of the patients (n =
25) were not complying at all. Compliance was improved
in 4.7% of the patients (n = 65) who did not comply at
first but complied at last. A total of 5.8% of the patients
(n = 79) showed a deteriorating compliance behavior by
complying initially (at first) but not complying at last.
Abstinence was measured in 52.3% of the patients
(n = 717; p = .0942). No nonprescribed psychoactive
substances were detected in both urine samples of those
patients. Conversely, (n = 655) 47.7% of the patients
showed in at least one unreported psychoactive substance
in at least one urine sample. No illicit psychoactive substance was found in the first urine sample, 69.5% of the
patients (n = 953; p < .0001) while 70.0% of the patients
(n = 960; p < .0001) had no illicit psychoactive substances
found in the last urine sample. During the first and last
urine specimen collections, 12.8% of the patients (n =
176) were not abstinent at all. Improvement in abstinence
was shown in 17.7% of the patients (n = 243) who were
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Table . The association between compliance and abstinence.
Compliance
Both

Abstinence
Both
First
Last

First

Last

OR

% C.I.

p value

OR

% CI

p value

OR

% CI

p value

.
.
.

(., .)
(., .)
(., .)

.
.
.

.
.
.

(., .)
(., .)
(., .)

.
.
.

.
.
.

(., .)
(., .)
(., .)

.
.
.

% CI = Ninety ﬁve percent conﬁdence interval

not abstinent at first but were abstinent at the last sample.
However, the abstinence of 17.2% of the patients (n = 236)
deteriorated as they were abstinent at first sample, but not
abstinent at last. Table 3 is a comparison of compliance
and abstinence.
Significantly, “abstinence both” is more likely for a
patient in “compliance both” than not (p = .0015). Also,
patients are more likely to be in “abstinence last” if they
were in “compliance both” (p = .0011). “Abstinence both”
is more likely than not for patients who were in “compliance last” (p = .0034). Also, “abstinence last” is more
likely for a patient who were in “compliance last” than not
(p = .0001). It seems that there is no statistically significant association between “abstinence first” and “compliance both/first/last” or “compliance first” and “abstinence
both/first/last.”
Table 4 shows the primary drug class used by nonabstinent patients that was found in at least one urine sample of nonabstinent patients (n = 655) and the association between that drug type and compliance to MAT. During treatment, from the first and last urine analysis almost
30% of the nonabstinent patients used psychostimulants,
31% used benzodiazepines, and 47% used opioids during treatment. Nicotine use was not considered in this

Table . The association between compliance and primary drug
class used by nonabstinent patients (part one).
Drug class
Psychostimulants
Hallucinogens (PCP, LSD, etc.)
Opioids (antitussives)
Benzodiazepines
(antianxiety)
Amphetamines
Cannabinoids
Ethanol

n (%)

OR

% CI

p value

 (.)
 ()
 ()
 ()

.
—
.
.

(., .)
—
(., .)
(., .)

.
.
.
.

 (.)
 (.)
 (.)

.
.
.

(., .)
(., .)
(., .)

.
.
.

PCP = Phencyclidine; LSD = Lysergic acid diethylamide

analysis. The odds ratios with the corresponding 95%
confidence intervals, estimated any association between
the misused drug and compliance to the bup/nal prescription of the nonabstinent patients. As the high p values
indicate, there was no statistically significant association
between the drugs misused and the compliance status.
Contingency analyses
The results of the contingency analysis of compliance and
abstinence as a function of five states (Table 5), treatment
modality (Table 6) and a comparison of compliance and
abstinence rates in 2010 and 2011 are presented here.

Table . Compliance and abstinence rates as a function of the ﬁve eastern states.
Compliance
State
MD
ME
NC
RI
VT
χ
p value

Abstinence

Both: n (%)

First: n (%)

Last: n (%)

Both: n (%)

First: n (%)

Last: n (%)

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

MD = Maryland; ME = Mein; NC = North Carolina; RI = Rhode Island; SC = South Carolina; VT = Vermont

Table . Compliance and abstinence as a function of the patients’ treatment modality.
Compliance

Abstinence

Modality

Both: n (%)

First: n (%)

Last: n (%)

Both: n (%)

First: n (%)

Last: n (%)

In-patient
Out-patient
χ
p value

 (.)
, (.)
.
.

 (.)
, (.)
.
.

 (.)
, (.)
.
.

 (.)
 (.)
.
.

 (.)
 (.)
.
.

 (.)
 (.)
.
.

SUBSTANCE USE & MISUSE

225

Table . Compliance and abstinence rates over level of care.
Compliance

Abstinence

Level of care

Both: n (%)

First: n (%)

Last: n (%)

Both: n (%)

First: n (%)

Last: n (%)

IP
RES
IOP
OP
OTP
χ
p value

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

 (.)
 (.)
 (.)
 (.)
 (.)
.
.

IP = In-patients; IOP = Intensive out-patients; OP = Out-patient; OTP = Opioid treatment programs; RES = Residential facility

There are overall statistically significant differences in
the compliance and abstinence rates among the five states.
VT exhibited the highest “compliance both” rate of over
90% while Maryland (MD) gave the lowest rate. VT also
showed the highest “abstinence both” rate of over 56%
while MD the lowest.
There is statistically (Table 7) significant evidence from
Fisher’s exact tests, to conclude, that out-patients adhere
to treatment medications better than in-patients (pboth =
.0257; plast = .0156). Except for the case of “compliance
first” where there was no statistically significant difference between the out-patients and the in-patients (pfirst
= .2908). On the other hand, the abstinence rates were
similar between the out-patients and the in-patients.
Among five different levels of care, the overall difference in compliance rates was not found to be statistically significant (p = .2699). However, “abstinence first”
(p = .0001) and “abstinence both” (p = .0175) were statistically significant over all levels of care. Although not
significant, the in-patients and the patients in the residential facility exhibited the lowest compliance rates. The
in-patients showed the greatest improvement with inpatients last and intensive out-patients having the highest
abstinence rates while the patients in the residential facility programs gave low abstinence rates consistently.
An annual comparison of compliance and abstinence
rates between the years 2010 and 2011 was not statistically significant. Compliance and abstinence during treatment at one facility over the 2 years of the urine sample
are presented. Patients (n = 152) 11.1% who had both the
first and last urine specimens collected in 2010, were compared to patients (n = 641) 46.7% who had both specimens collected in 2011. A further regression analysis also
found that changes over time were not statistically significant.

Figure . Cumulative compliance frequency over days in .

Figure 1 illustrates a longitudinal trend of compliance
in the subset of patients (n = 1,299) improved compliance
rates observed over time are implied by a statistically significant upward trend (p < 2.2 × 10−16 ).
In Figure 2 the general, overall upward trend observed
was statistically significant (p = 2.2 × 10−16 ), which
implies improved abstinence rates over time in the
same subset of the patients (n = 1,299) as is seen in
Figure 1.
The number of times a not-reported substance was
found in the specimens of n = 662 patients was n = 906.
Some of the nonabstinent patients were polydrug users

Part 2. Longitudinal analysis of all samples tested in
2011 (n = 1,299)
The results of the longitudinal analysis are illustrated in
Figures 1 and 2 and Table 8.

Figure . Cumulative abstinence frequency over days in .
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Table . Primary types drug used by the patients (n = ) %
who were not abstinent in .
Drug class
Amphetamines
Barbiturates
Benzodiazepines
Cannabinoids

(n = ) (%)
 (.)
 (.)
 (.)
 (.)

Drug class
Ethanol
Hallucinogens
Cocaine
Opioids

(n = ) (%)
 (.)
 (.)
 (.)
 (.)

Notes: Opioids = Semisynthetic opioids such as heroin, oxycodone, and
methadone (NAABT).

during treatment. Cannabinoids were found in 39% of
samples, opioids 27.4% and benzodiazepines in 14.7%.
Nicotine use was not considered in this analysis.

Discussion
These clinically relevant results show that although significant illicit opioid use was present in this cohort
(Part 1), a significant reduction of illicit opioid use was
demonstrated in the longitudinal analysis (Part 2). Significant strong compliance was shown and should encourage
the continued and expanded utilization of bup/nal. However, a study by Balhara & Jain (2012) utilizing urine drug
testing in a relatively small sample evaluated patients for
1-year and found that urinalysis failed to detect bup/nal
in 44.7% of the samples. In the current experiment, the
analysis found much higher compliance to bup/nal, with
a noncompliance of 12% overall.
Statistical analysis of the first and last urine samples
in this large cohort revealed an almost 50% nonabstinent rate during active treatment. These results are consistent with Bentzley, Barth, Back, & Book, who found
that every study they reviewed reported that, 1 month following discontinuation of bup/nal, relapse to illicit opioid use exceeded 50%. Together these results support the
routine use of urine drug screening among individuals in
programs for treatment for opioid dependence (Bentzley,
Barth, Back, & Book, 2015).
A study from Iran provided some evidence that compared to oral naltrexone; the employment of bup/nal
was associated with greater number of opioid-negative
UDS and better treatment retention (Mokri, Chawarski,
Taherinakhost, & Schottenfeld, 2016). Subramaniam
et al. (2011) evaluated predictors of abstinence from
National Institute on Drug Abuse (NIDA) multisite
bup/nal treatment trial in opioid-dependent youth. They
found that youth reporting injection drug use, and those
receiving adjuvant treatments for additional health problems, were more likely to have a lower opioid use. In
another study, the same group looked for predictors
of attrition for the duration of bup/nal treatment and
found that retention can be improved by giving attention during the first 2 weeks of treatment to medication

noncompliance, or an early opioid-positive urine tests
(Warden et al., 2012).
The current longitudinal analysis (Part 2) showed that
adherent patients had progressive increases in abstinence
rates. These results and the above studies confirm the
clinical observation that patients who comply with opioid agonist medications are more likely to be adherent
to their addiction treatment plan. Cross-sectional data
analysis demonstrates that polysubstance use is the norm
initially, with longitudinal analysis showing continued
improvement of treatment outcome over time. This study
has clearly shown, with a 1.70 odds ratio and a very
high p value (2.2 × 10−16 ), that medication adherence
is essential to the successful management of patients in
chemical-dependency programs.
The reduction in the use of nonprescribed opioids during treatment, found in the longitudinal analysis (Part 2)
of this cohort of bup/nal patients, is significant. When
viewed from a harm-reduction perspective, the finding of
cannabis in 38% of UDS, and benzodiazepines in 14.1%
could be considered a significant accomplishment if they
were used rather than opioids.
Compliance rates as high as 92% demonstrate the amelioration of bup/nal diversion in programs, like those
in this study, that provide integrated on-site counseling and urine drug testing against known doses of
bup/nal. This information should support the elimination
of nonstandard-of-care practices, which drive the diversion of buprenorphine in the form of bup/nal.
Limitations
Most drugs are detectable for up to 1–3 days in urine;
some like cannabis can be detected after 2 weeks. Urine
remains stable over time, can be frozen and is considered
a biological hazard for specimen handling and shipping.
Urine drug tests are sometimes viewed as psychologically
invasive because sample collection is directly observed,
to prevent methods that interfere with testing accuracies, such as dilution, adulteration, or urine substitution.
An important limitation is that there is no relationship
between the dose and urine concentration of a drug (Tam,
2017) and because urinalysis, as utilized here, frequency
or extent of drug use cannot be determined.
Initially, the data were cleaned in the preprocessing
stage of the analysis. The proportion of missing data
was very small since we only observed the first and last
specimens per patient in Part 1. Imputation was not
advised at that time since it could have caused more
biases with few specimens looked at per patient. The
longitudinal analysis (Part 2) was based on laboratory
data derived from each patient sample tested in 2011. In
this subset, the lack of rich clinical correlation prevents
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extrapolation of group data to individual patients. For
example, due to unknown variations in the testing intervals and drug use frequently among recovering patients,
we cannot know, the actual percentage of patients who
used opioids. Table 8 represents the percentages of drug
types used at the time and frequency at which the samples
were taken. Among 622 patients there were 934 instances
of unreported drug use. Such limitations should spur
further longitudinal research with expanded clinical
datasets, aided by the development of more standardized
clinical assessment instruments such as the American
Society of Addiction Medicine (ASAM) criteria software,
genetic analyses, and comprehensive analysis of UDS
reporting.
The limitation on extrapolation of group data was
avoided in the initial cross-sectional analysis of data from
first and last urine samples (Part 1) when 308 of nonabstinent patients were found to be using opioids. However,
there could have been a failure to protect against surveillance bias; variations in drug use behaviors on admission and discharge from programs may have influenced
this result, for example, discharge against medical advice
was not assessed in this study. Other caveats in this study
include lack of Type ll power analysis. There were some
confounding effects present in the inception cohort; all
CARDTM data available from 2010 to 2011. For example,
the differential length of follow-up (the number of days
between the first and last urine samples varied from 15 to
717 days). Another effect may be that the first urine samples taken following bup/nal combination therapy when
high levels of illicit drugs might be present could result
in an exaggeration of the improvement seen in the subsequent longitudinal linear trend.
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neural mechanisms that elicit reward-seeking and relapse
in addictive behaviors (Volkow, Fowler, Wang, Telang,
& Baler, 2009) are encouraged. To further enlighten our
understanding of the psychological status of recovering
patients, larger studies are required. A planned extension
of this work will include a panel of reward gene polymorphic candidates, CARD analysis, the Addiction Severity Index (ASI) and ASAM criteria software in polydrug
users attending an in-patient 28-day residential program.
We encourage the development of thoughtful new strategies like a pharmacogenetic approach to the treatment
of opioid dependence to target the specific brain regions
responsible for relapse and opioid addiction (Lawford
et al., 2000).
These clinically relevant results, with limitations,
showing a significant reduction of illicit opioid use and
strong compliance, should further encourage the cautious
continued and expanded utilization of to bup/nal (Blum,
Gold, Clark, Dushaj, & Badgaiyan, 2016). Meanwhile, the
long-term use of bup/nal, because of the potential for
addiction liability and antireward effects, requires further intensive investigation (Elman et al., 2013; Hill et al.,
2013). We believe that these results will provide active
organizations including the National Alliance of Advocates for Buprenorphine Treatment (NAABT) with informative UDS reporting that can help the OUD community
in the future.
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